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(1) Overview
Project description
The aim of our work has been to build and to strengthen a 
Public Oncologic Serum Biobank (BPMSO) that collects 
and stores high quality biosamples with corresponding 
clinico-pathological associated data, providing an invalu-
able resource of information for research on cancer and 
discovering serum tumour biomarkers.
The primary goal for the biobank establishment was 
to invite and recruit patients with “clear cell type Renal 
Carcinoma”, in any stage of the disease and undergoing 
different types of treatment, for which serum levels of dif-
ferent cytokines were measured, in order to understand 
how these molecules are associated with, not only early 
diagnosis of this tumour type but also with the outcome 
of treatment.
All patients had previously consented to participate 
signing a written IC document.
All clinical and epidemiological data are gathered by well 
trained professionals. These data are saved and stored in a 
secure way – link anonymized- so as to protect patient´s 
privacy and confidentiality respecting data access rules.
Clinical patient´s medical records are periodically 
revised as to be sure the databases are reviewed and 
updated.
Between the different molecules described in “renal cell 
carcinoma”[1, 2, 3], it seems clear to us that many can be 
involved in metabolic pathways deregulation[4, 5], but 
carbonic anhydrase IX (CAIX) and angiopoietin-2 (Ag2) 
have been demonstrated to have an active and prominent 
role[6, 7].
As a “Public Oncologic Serum Biobank” associated 
research project, our multidisciplinary research team has 
focused in studying different and circulating serum bio-
markers in patients with renal carcinoma.
So far, the Public Oncologic Serum Biobank has col-
lected the number and type of biosamples as indicated 
below:
•	 Renal Cancer: 270
•	 Breast Cancer: 68
•	 Ovarian cancer: 10
•	 Donor Volunteers: 78
•	 N° Total alicuots: 9394
Every research protocol requesting samples from our 
biobank, must always be previously submitted to the IRB 
for approval.
Even though we have not yet established in our Best 
Practices, how long the biosamples will be stored, and also 
if the leftover material might be re-used once the samples 
has been utilized by the researchers, we work in close col-
laboration with the Research Ethic Committee (REC) for 
open consultation concerning this issue and others that 
might arise in the course of biobanking management.
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Human
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Classification (2)
Biological samples and associated data 
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Context
Spatial coverage
Latitude-Longitude
-34.596933, -58.49458
Description: Argentina- Buenos Aires-Institute of 
Oncology “Ángel H. Roffo”-University of Buenos Aires- Av. 
San Martín 5481- PC:1417.
•	 Northern boundary: +/- x.x
•	 Southern boundary: xx
•	 Eastern boundary: +/- x.x
•	 Western boundary: +/- x.x
Temporal coverage
Start date: March 2008. End date: not applicable (the pro-
spective cohort will be followed-up as long as possible); 
this implies that we do not have any time limitation for 
data and sample collection process.
(2) Methods
Venous blood samples (15-20 ml) are collected by veni-
puncture from recruited patients and donor volunteers, in 
10 ml tubes with beads as clot activator and without any 
anticoagulant, after an overnight fast.
Stabilization/preservation
The samples are transported to the laboratory for process-
ing as soon as possible.
The blood is left to stand for 10 min at room tempera-
ture and then centrifuged in a hematologic refrigerated 
centrifuge( 4°C) (3000 rpm x 10 min).
Serum is fractionated in sterile conditions (SBC: Security 
Biological Cabinet), in approximately 20-22 aliquots of 
400 ul each.
Type of long-term preservation
Vertical ultra-cold temperature freezers
Storage temperature
•	 Samples are stored at -80° C
•	 Long term future storage duration is not defined yet 
(may be 20 years or more)
Shipping temperature from patient/source to pre­
servation or research use
Transportation from each collection site to the central lab, 
at room temperature in no more than 15-20 min
Shipping temperature from storage to research use
Transportation to the central Biobank to research use 
within 24 hours in dry-ice. 
Quality assurance measures
We follow at all time our local SOPs for “best practices”, 
adapted from international standards documents: NCI-
ISBER-IARC-OECD Guidelines for Biorepositories.
Source of associated data
Questionnaires, personal health data from medical 
records with other comorbid conditions such as diabetes, 
hypertension, tobacco, COPD, etc.
Personal and family cancer history background is also 
registered. 
Ethics statement
National Law N° 25352 on personal data privacy protec-
tion (Approved by Parliament) and other regulations. 
Revised and updated to January 2008.
Constraints
None, except National Regulation on personal data and 
biological materials.
(3) Bioresource description
Object name
Collecting serum samples from cancer patients.
Bioresource name
Public Oncologic Serum Biobank ( BPMSO: Biobanco 
Público de Muestras Séricas Oncológicas). We work in 
separate areas but in conjunction with the “Tumor tissue 
Bank”.
Bioresource location
Institute of Oncology “Ángel H. Roffo”
Research Área
University of Buenos Aires
Av. San Martín 5481
PC1417- Buenos Aires
Argentina
Bioresource contact
Email:
prondotuba@hotmail.com
pedrorondotradio@ymail.com
lydiapur@yahoo.com
informes@institutoroffo.com.ar
Bioresource URL
http://www.institutoroffo.com.ar/
Identifier used
N/A
Bioresource type
Oncologic Serum Biobank
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Type of sampling
Prospective population cohort, not only from cancer 
patients but also healthy donors.
Anatomical site
Any type of cancer
Disease status of patients/source
Patients with cancer, before going to surgery or any other 
kind of treatment (QT); registering all events occurring 
during their treatment follow-up.
Clinical characteristics of patients/source
All Cancer patients aged >18-70 at enrolling time since 
2009. Personal and health data retrospective and prospec-
tively collected.
Vital state of patients/source
•	 Living patients and healthy controls.
•	 Personal clinical records, with periodic and timely 
reviewing every 4-6 months, for data up-date.
Clinical diagnosis of patients/source
For cancer and other clinical or comorbid conditions, con-
firmation is made through medical records. 
Pathology diagnosis
•	 Available through medical records.
•	 TNM staging or ICD-10 classification.
Control samples
Most of the cohort volunteers are healthy women and 
men, who donate blood at the “hemotherapy and transfu-
sion department.
Biospecimen type
Only serum for the moment. We plan to store plasma and 
buffy-coat too, in the near future.
Size of the bioresource
582 participants at present; collecting project still 
continuing.
Release date
Cancer serum biosamples are already available to be dis-
tributed and used by the research community at large, 
national and international.
Access criteria
According to national law and local IRB, every research 
group (public or private; national or international) is enti-
tled to apply for a research project through a formal local 
application designed with that purpose (objectives; type 
and number of samples requested; data needed; timeta-
ble); the PI must present an approved research protocol, 
and all legal and ethical authorizations must be provided.
In the case of transferring samples across borders, sign-
ing a MTA is necessary.
As a cost-recovery plan, a financial contribution is asked 
in the case of biosamples transfer or shipment.
(4) Reuse potential
Researchers must use the samples and associated data 
respecting the Data Privacy Local Act, in accordance 
with the MTA which must be signed in total agreement 
between the parties.
Author roles
1. Reviews the “research protocols” that are associated 
with the biobank, approves and submits them to 
the “Institutional Review Board” for consideration 
and final approvement, in close collaboration with 
the Deputy-CEO.
2. Director- Curator of data- Samples collect & pro-
cessing. Samples tracking & custodianship. Control 
of databases with encryption. Guarantees patients’ 
privacy and confidentiality respecting national and 
international norms regarding data access rules.
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